Snubbed at the FDA, PTC files their three-time loser for Duchenne MD over protest
PTC Therapeutics $PTCT isn’t going to let a slate of three consecutive, failed studies for ataluren block its review at the FDA. Using …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
